Experience in the use of oral lipid-lowering medicines in a group of patients followed in 12 colombian cities

espanolIntroduccion: Los estudios de utilizacion de medicamentos sirven para evaluar la efectividad y seguridad de los farmacos en la practica real, diferente al contexto del estudio clinico controlado. Los hipolipemiantes actuan sobre el perfil lipidico disminuyendo el riesgo de enfermedades cardiovasculares. Objetivo: Describir el desempeno clinico y seguridad de la utilizacion de medicamentos hipolipemiantes en la practica medica real en una cohorte de pacientes con diagnostico de dislipidemia. Metodologia: Estudio observacional de cohorte.Se siguio una cohorte de pacientes con indicacion de hipolipemiantes durante 6 meses, en 12 ciudades de Colombia pertenecientes a un registro biomedico de seguimiento de pacientes tratados con medicamentos del portafolio de Abbott. Se midieron variables demograficas y clinicas basales, de seguridad y de desempeno clinico de los medicamentos sobre el perfil lipidico a los 3 y 6 meses. Resultados: Se siguieron 501 pacientes en tratamiento con hipolipemiantes. Las estatinas solas disminuyeron el colesterol de baja densidad de 249 mg/ dL (RIQ=226-268) en la medicion basal a 190 (177.6-210) y 170 (108-170) en la segunda y tercera medicion, respectivamente. Para estatina + ezetimibe, de 167 mg/dL (RIQ=139-184) a 132 (110-150) y 128.5 (101.5-128.5). El fenofibrato disminuyo los trigliceridos de 275 mg/dL (RIQ=219346) a 201 (172-239) y 150.5 (140-150.5). Conclusiones: la administracion de estatinas sola o en combinacion disminuyo los niveles de LDL y colesterol total, mientras que el fenofibrato demostro su efectividad al disminuir los trigliceridos. No se reportaronefectos adversos. Hubo una adherencia parcial del medico tratante a la guia de practica clinica para dislipidemias. MED.UIS.2019;32(1):13-20. Englishintroduction: Drug use studies are important to evaluate the effectiveness and safety of drugs in daily practice, outside the controlled clinical study. Lipid-lowering drugs act on the lipid profile, decreasing the risk of cardiovascular diseases. Objective: To describe the clinical performance and safety of the use of lipid-lowering drugs in real practice in a group of patients diagnosed with dyslipidemia. Methods: An observational, descriptive cohort study. A cohort of patients with hypolipidemic indication for 6 months was followed in 12 cities of Colombia that belong to the biomedical registry of follow-up of patients treated with medicines from the Abbott portfolio. Baseline demographic and clinical variables, safety and efectivity of the drugs were measured on the lipid profile at 3 and 6 months. Results: 501 patients received lipid-lowering agents. Statins alone decreased the low density (LDL) cholesterol of 249 mg / dL (RIQ = 226-268) at baseline to 190 (177.6-210) and 170 (108-170) at the second and third measurements, respectively. For statin + ezetimibe, from 167 mg / dL (RIQ = 139-184) to 132 (110-150) and 128.5 (101.5-128.5). Fenofibrate decreased triglycerides from 275 mg / dL (RIQ = 219-346) to 201 (172-239) and 150.5 (140-150.5). Conclusions: The administration of statins alone or in combination decreased LDL and total cholesterol levels, while fenofibrate demonstrated its effectiveness in lowering triglycerides. No adverse effects were reported. There was partial adherence of the treating physician to GPC for dyslipidemias. There were no adverse events. MED.UIS.2019;32(1):13-20.